Real-World Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis: A 24-Month Italian National Registry Study
In this nationwide real-world cohort, ETI was associated with sustained improvements in lung function, nutritional status, and hospitalization burden. The attenuation of lung function gains after the first year, particularly in less severe disease, supports the need for individualized monitoring and cautious treatment de-escalation in the ETI era.
Authors
- Annalisa Amato (ORCID: https://orcid.org/0009-0009-0591-4366)
- Donatello Salvatore (ORCID: https://orcid.org/0000-0003-2432-415X)
- Giuseppe Campagna (ORCID: https://orcid.org/0000-0002-1884-9171)
- Rita Padoan (ORCID: https://orcid.org/0000-0002-0624-8125)
- Angela Pepe (ORCID: https://orcid.org/0000-0002-5801-0397)
- M. Salvatore
Institutions
- Ospedale San Carlo (IT)
- Cystic Fibrosis Research Foundation (IT)
- Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases (AT)
- Sapienza University of Rome (IT)
Publication Details
- Journal
- Journal of Clinical Medicine
- Published
- 2026-04-02
- DOI
- https://doi.org/10.3390/jcm15072699
- Primary Topic
- Cystic Fibrosis Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 0.00